Search
Phenindamine
go.drugbank.com/drugs/DB01619ApprovedSymptoms of a phenindamine overdose include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and … Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body.
Budiodarone
go.drugbank.com/drugs/DB05519InvestigationalBudiodarone (ATI-2042) is an antiarrhythmic related to amiodarone that is currently being studied in clinical trials.
FavId
go.drugbank.com/drugs/DB05249InvestigationalFavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.
Amelubant
go.drugbank.com/drugs/DB06248InvestigationalSynonyms: Carbamic acid, N-[[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]phenyl]methoxy]phenyl]iminomethyl]-, ethyl esterEGS21
go.drugbank.com/drugs/DB05056ExperimentalEGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders. … GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate
Perospirone
go.drugbank.com/drugs/DB08922InvestigationalClassified as a neuroleptic agent, perospirone is shown to be effective against positive, negative and general symptoms in patients with schizophrenia [A19676]. … It also displays affinity towards 5HT1A receptors as a partial agonist.
Synonyms: cis-N-(4-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximideTilmanocept
go.drugbank.com/drugs/DB15373ApprovedInvestigationalWithdrawnTilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed … With Rheumatoid Arthritis (RA)).
LU-31130
go.drugbank.com/drugs/DB05828ExperimentalLU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders. … It acts at the Dopamine D4 receptors in the cortex and has low affinity for D2 receptors, adrenoceptors, muscarinic and histaminergic receptors.
Fasedienol
go.drugbank.com/drugs/DB04968InvestigationalIt is a member of a new family of pharmaceutical compounds called vomeropherins. … PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder).